Morgan Stanley analyst Craig Hettenbach raised the firm’s price target on Hinge Health (HNGE) to $57 from $46 and keeps an Overweight rating on the shares. Revenue growth and the forward trajectory cleared “a high bar” with a “solid beat and raise” report, the analyst tells investors. The firm is increasing its annual revenue estimates by 8% and its EBIT estimates are “more than doubling” in 2025 as the company “delivered exceptional incremental margins,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE: